American multiple myeloma patient Andrew Sninsky, 75, is cycling around New Zealand to raise awareness of a cancer without a cure. Myeloma is a...
Myeloma NZ
Time taken for Pharmac funding decisions ‘too long’, says Medicines NZ
It takes the nation’s drug-buying agency, Pharmac, an average of 7.7 years to make funding decisions about potentially life-saving medicines, a...
Cancer patients harmed by ongoing treatment delays at Southern health board
In the first two months of 2021, 27 patients were harmed by cancer treatment delays, the Otago Daily Times reported. Three became so...
Therapeutic Products Bill Submission!
Myeloma New Zealand has made a submission on the Therapeutic Products Bill, as it has implications for Myeloma Patients. The Chair of the Health...
In Focus: From the lab to the clinic in New Zealand’s first CAR T-cell therapy clinical trial
Nathaniel works in the research team, where the CAR T-cells are designed, and supports both the GMP team, where the CAR T-cells are manufactured,...
FRAIL-M Study for Newly-Diagnosed Multiple Myeloma
The Australasian Myeloma Research Consortium (AMaRC) in collaboration with theAustralasian Leukaemia & Lymphoma Group (ALLG) and the Myeloma and...
Consensus statement on the treatment of transplant eligible patients with newly diagnosed multiple myeloma in New Zealand
The New Zealand Myeloma Interest Group is comprised of representative haematologists from District Health Boards around the country with a special...
Dr Ken Romeril, Multiple Myeloma founder, Member of the NZ Order of Merit, advocates for the desperate need for access to modern medicines for myeloma sufferers.
https://www.stuff.co.nz/opinion/300759926/miracle-medicines-a-cancer-specialist-sends-a-message-to-pharmac
Multiple Myeloma Summit 2022
Myeloma experts convened in person and online for the 2022 Multiple Myeloma Queenstown Summit, hosted by Myeloma New Zealand. This year’s meeting...
Multiple Myeloma NZ campaigns for Pharmac to fund medicine
Myeloma New Zealand has started a campaign to press Pharmac into funding a treatment that has been standard-of-care throughout the Organisation for...
BLOOD CANCER PATIENTS IMPLORE PHARMAC TO FUND DESPERATELY NEEDED MEDICINE
MEDIA RELEASE 7 September 2022 New Zealanders living with multiple myeloma, a deadly, relapsing/remitting blood cancer, are mounting a major,...
Multiple Myeloma Research Review
Multiple_Myeloma_Research_Review_Issue_43Download